Table 4.
Base-case cost-effectiveness results comparing all medications
| Costs (£) | QALYs | Incremental costs (£) | Incremental QALYs | ICER: cost per QALY gained (£) | Comparison | |
|---|---|---|---|---|---|---|
| Deterministic results—discounted | ||||||
| Topiramate | £1,625 | 1.3995 | - | - | - | |
| Placebo | £1,729 | 1.3531 | £104 | -0.0464 | Dominated | Placebo vs. Topiramate |
| BTA | £3,654 | 1.4294 | £2,029 | 0.0298 | £68,002 | BTA vs. Topiramate |
| Fremanezumab (monthly) | £10,155 | 1.4403 | £6,501 | 0.0013 | Extendedly dominated | Fremanezumab (monthly) vs. BTA |
| Fremanezumab (quarterly) | £10,193 | 1.4224 | £38 | -0.0083 | Dominated | Fremanezumab (quarterly vs. monthly) |
| Eptinezumab 100 | £10,216 | 1.4239 | £22 | -0.0067 | Dominated | Eptinezumab 100 vs Fremanezumab (monthly) |
| Galcanezumab | £10,640 | 1.4229 | £485 | -0.0078 | Dominated | Galcanezumab vs. Fremanezumab (monthly) |
| Eptinezumab 300 | £27,401 | 1.4403 | £17,246 | 0.0097 | £2,160,037 | Eptinezumab 300 vs BTA |
| Probabilistic results—discounted | ||||||
| Topiramate | £1,624 | 1.4045 | - | - | - | |
| Placebo | £1,728 | 1.3460 | £104 | -0.0584 | Dominated | Placebo vs. Topiramate |
| BTA | £3,654 | 1.4270 | £2,030 | 0.0226 | £89,939 | BTA vs. Topiramate |
| Fremanezumab (monthly) | £10,161 | 1.4350 | £6,507 | 0.0080 | Extendedly dominated | Fremanezumab (monthly) vs. BTA |
| Fremanezumab (quarterly) | £10,196 | 1.4273 | £34 | -0.0078 | Dominated | Fremanezumab (quarterly vs. monthly) |
| Eptinezumab 100 | £10,221 | 1.4199 | £59 | -0.0151 | Dominated | Eptinezumab 100 vs Fremanezumab (monthly) |
| Galcanezumab | £10,646 | 1.4161 | £485 | -0.0189 | Dominated | Galcanezumab vs. Fremanezumab (monthly) |
| Eptinezumab 300 | £27,411 | 1.4365 | £17,250 | 0.0014 | £2,524,429 | Eptinezumab 300 vs BTA |
Extendedly dominated is where any interventions that have an ICER which is greater than that of a more effective intervention is ruled out